These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 38619788)
41. A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis. Singh RP; Srivastava S; Ehlers JP; Bedi R; Schachat AP; Kaiser PK Br J Ophthalmol; 2014 Jun; 98 Suppl 1(Suppl 1):i22-27. PubMed ID: 24836866 [TBL] [Abstract][Full Text] [Related]
42. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD. Waizel M; Todorova MG; Masyk M; Wolf K; Rickmann A; Helaiwa K; Blanke BR; Szurman P BMC Ophthalmol; 2017 May; 17(1):79. PubMed ID: 28535756 [TBL] [Abstract][Full Text] [Related]
43. Cost of Ranibizumab Port Delivery System vs Intravitreal Injections for Patients With Neovascular Age-Related Macular Degeneration. Sood S; Mandell J; Watane A; Friedman S; Parikh R JAMA Ophthalmol; 2022 Jul; 140(7):716-723. PubMed ID: 35708679 [TBL] [Abstract][Full Text] [Related]
44. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis. Ba J; Peng RS; Xu D; Li YH; Shi H; Wang Q; Yu J Drug Des Devel Ther; 2015; 9():5397-405. PubMed ID: 26451092 [TBL] [Abstract][Full Text] [Related]
45. Switch to Aflibercept in the Treatment of Neovascular AMD: One-Year Results in Clinical Practice. Pinheiro-Costa J; Costa JM; Beato JN; Freitas-da-Costa P; Brandão E; Falcão MS; Falcão-Reis F; Carneiro ÂM Ophthalmologica; 2015; 233(3-4):155-61. PubMed ID: 25896317 [TBL] [Abstract][Full Text] [Related]
46. Choroidal Effusion following Intravitreal Brolucizumab Injection: A Case Report. Sim HE; Kim JS; Hwang JH Case Rep Ophthalmol; 2022; 13(1):166-171. PubMed ID: 35611023 [TBL] [Abstract][Full Text] [Related]
47. A Comparative Study of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration: 12-Month Outcomes of Polish Therapeutic Program in Non-Tertiary Institution. Skrzypczak T; Jany A; Bugajska-Abramek E; Bogusławska J; Kowal-Lange A Cureus; 2021 Jun; 13(6):e15916. PubMed ID: 34336421 [TBL] [Abstract][Full Text] [Related]
48. Two Year Study of Aflibercept and Ranibizumab Intravitreal Therapy in Patients with Wet AMD. Luksa D; Heinke A; Michalska-Małecka K Medicina (Kaunas); 2021 Nov; 57(12):. PubMed ID: 34946238 [No Abstract] [Full Text] [Related]
49. Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial. Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Ng P; Pecheur FL; McAllister IL JAMA Ophthalmol; 2019 Apr; 137(4):372-379. PubMed ID: 30676617 [TBL] [Abstract][Full Text] [Related]
50. Efficacy Outcomes of Brolucizumab Versus Aflibercept in Neovascular Age-Related Macular Degeneration Patients with Early Residual Fluid. Singh RP; Jhaveri C; Wykoff CC; Gale RP; Staurenghi G; Iida T; Koh A; B G; Gedif K; Singer M Ophthalmol Retina; 2022 May; 6(5):377-386. PubMed ID: 34968756 [TBL] [Abstract][Full Text] [Related]
51. Real-World Experience with Brolucizumab Compared to Aflibercept in Treatment-Naïve and Therapy-Refractory Patients with Diabetic Macular Edema. Rübsam A; Hössl L; Rau S; Böker A; Zeitz O; Joussen AM J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38542043 [No Abstract] [Full Text] [Related]
52. Injection frequency and anatomic outcomes 1 year following conversion to aflibercept in patients with neovascular age-related macular degeneration. Messenger WB; Campbell JP; Faridi A; Shippey L; Bailey ST; Lauer AK; Flaxel CJ; Hwang TS Br J Ophthalmol; 2014 Sep; 98(9):1205-7. PubMed ID: 24795334 [TBL] [Abstract][Full Text] [Related]
53. Evaluating initial responses to brolucizumab in patients undergoing conventional anti-VEGF therapy for diabetic macular edema: a retrospective, single-center, observational study. Hirano T; Kumazaki A; Tomihara R; Ito S; Hoshiyama K; Murata T Sci Rep; 2023 Jul; 13(1):10901. PubMed ID: 37407660 [TBL] [Abstract][Full Text] [Related]
54. One-Year Brolucizumab Outcomes in Neovascular Age-Related Macular Degeneration from a Large United States Cohort in the IRIS® Registry. MacCumber MW; Wykoff CC; Karcher H; Adiguzel E; Sinha SB; Vishwakarma S; LaPrise A; Igwe F; Freitas R; Ip MS; Zarbin MA Ophthalmology; 2023 Sep; 130(9):937-946. PubMed ID: 37086857 [TBL] [Abstract][Full Text] [Related]
55. Ranibizumab versus aflibercept for the treatment of vascularized pigment epithelium detachment due to age-related macular degeneration. Rouvas A; Chatziralli I; Androu A; Mpougatsou P; Alonistiotis D; Douvali M; Kabanarou SA; Theodossiadis P Int Ophthalmol; 2019 Feb; 39(2):431-440. PubMed ID: 29404860 [TBL] [Abstract][Full Text] [Related]
56. A Real-World, Multicenter, 6-Month Prospective Study in Greece of the Effectiveness and Safety of Ranibizumab in Patients with Age-Related Macular Degeneration Who Have Inadequately Responded to Aflibercept: The "ELEVATE" Study. Rouvas A; Datseris I; Androudi S; Tsilimbaris M; Kabanarou SA; Pharmakakis N; Koutsandrea C; Charonis A; Kousidou O; Pantelopoulou G Clin Ophthalmol; 2022; 16():2579-2593. PubMed ID: 35983162 [TBL] [Abstract][Full Text] [Related]
58. Real-World Evidence in the Management of Diabetic Macular Edema with Intravitreal Anti-VEGFs in Asia: A Systematic Literature Review. Yuen YS; Tan GSW; Gan NY; Too IHK; Mothe RK; Basa P; Shaikh J Clin Ophthalmol; 2022; 16():3503-3526. PubMed ID: 36274678 [TBL] [Abstract][Full Text] [Related]
59. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Cho H; Shah CP; Weber M; Heier JS Br J Ophthalmol; 2013 Aug; 97(8):1032-5. PubMed ID: 23766432 [TBL] [Abstract][Full Text] [Related]
60. [Switching Therapy from Ranibizumab and/or Bevacizumab to Aflibercept in Neovascular Age-Related Macular Degeneration (AMD): One-Year Results]. Pfau M; Fassnacht-Riederle HM; Freiberg FJ; Wons JB; Wirth M; Becker MD; Michels S Klin Monbl Augenheilkd; 2016 Aug; 233(8):945-50. PubMed ID: 27123887 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]